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Background: Acute myeloid leukemia mainly affects adult patients. Complete remission for 
patients younger than 60 years, who are candidates for standard induction therapy, is achieved 
in 60%–80% of cases. However, the prognosis is still poor for older patients, who are unfit 
for intensive chemotherapy, and only a few therapies are available. Hypomethylating agents, 
such as decitabine, are approved for such patients. The current dosing regimen consists of one 
administration per day, for 5 days, each 4 weeks.
Methods: Here, we present the synthesis of a decitabine prodrug, combined with its encapsula-
tion into a lipid-based nanocapsule formulation. Decitabine (C12)
2
 was synthetized, then loaded 
into nanocapsules. Its stability in phosphate buffer ans human plasma was checked. Its activity 
was evaluated by Cell proliferation assays and cell-cycle analysis on human erythroleukemia 
cells. Then its pharmacokinetics was determined on a rat model.
Results: Decitabine (C12)
2
 was obtained with a yield of 50%. Drug loading into nanocarriers 
of 27.45±0.05 nm was 5.8±0.5 mg/mL. The stability of decitabine was improved and its activ-
ity on leukemia cells was not altered. Finally, pharmacokinetics studies showed a prolonged 
mean residence time of the drug.
Conclusion: Decitabine (C12)
2
 as a prodrug showed high encapsulation efficiency, a good stabil-
ity in plasma with no impact on its activity on leukemia cells and improved pharmacokinetics.
Keywords: lipid nanocapsules, acute myeloid leukemia, decitabine, nanomedicines, prodrugs
Introduction
Acute myeloid leukemia (AML) is a heterogenous hematological malignancy caused 
by the uncontrolled clonal expansion of leukemic progenitor cells. The incidence of 
AML increases with age, with a median of 64 years at presentation.1 Despite recent 
progress in the development of new therapeutics, the prognosis is still poor, with the 
5-year relative survival estimated to be 19% in Europe.2
Induction treatment for AML is based on a chemotherapeutic regimen consisting 
of a combination of an anthracycline (daunorubicin, doxorubicin, or idarubicin) and 
cytarabine. Only younger patients, who can support this intensive regimen (cytarabine 
100–200 mg/m2/day for 7 consecutive days and daunorubicin 60 mg/m2 or idarubicin 
12 mg/m2 on days 1–3), receive such treatment. Such intensive chemotherapy leads to 
complete remission in 60%–80% of younger patients, whereas it is obtained in ,30% 
in patients who are older than 60 years.3
For patients who are unfit to receive standard induction therapy, non-curative thera-
pies are proposed, such as low-dose cytarabine, hypomethylating agents (azacytidine 
or decitabine), or best supportive care. The prognosis is poor for these patients, with a 
1-year from diagnosis survival rate of ,30%.4 For such patients, decitabine (Dacogen®, 
Janssen-Cilag, Beerse, Belgium) received European marketing authorization in 2012, 
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whereas such authorization was not issued by the Food and 
Drug Administration (FDA) in the USA.
To be effective, azacytidine and decitabine need to be 
in contact with cells for a sufficient time to induce DNA 
hypomethylation.5,6 However, the half-life of decitabine in 
plasma is only 15–25 minutes.7 The drug, thus, needs to be 
administered once a day, for 5 days, each month. Longer 
exposure times (10-day schedules) appear to improve the 
response rate.8 Such a short half-life could be explained 
by rapid degradation due to cytidine deaminase. This deg-
radation pathway is also encountered during cytarabine 
administration. A liposomal formulation of cytarabine and 
daunorubicin (Vyxeos®, Jazz Pharmaceuticals) has just been 
approved by the FDA to treat newly diagnosed therapy-
related AML and AML with myelodysplasia-related changes. 
This formulation was proven to be capable of protecting cyta-
rabine from cytidine deaminase degradation,9 demonstrating 
the promise of new formulations, such as nanocarriers, to 
improve AML treatment. Patients receiving Vyxeos® lived 
longer than those who received separate treatments of dau-
norubicin and cytarabine, with the median overall survival 
prolonged from 5.95 to 9.56 months.10 Further improvement 
of the formulation of decitabine is, thus, desirable to enhance 
its half-life and efficacy.
Various strategies have been proposed to overcome the 
short half-life of decitabine. For example, guadecitabine, 
a decitabine prodrug composed of a dinucleotide of decitabine 
linked to a deoxyguanosine with a phosphodiester bond, is 
currently being tested in clinical trials (NCT02348489 and 
NCT02920008). The phosphodiester bond present in gua-
decitabine is cleaved gradually, resulting in the slow release 
of decitabine, extending its half-life in vivo. Guadecitabine 
is also less subject to cytidine deaminase action than 
decitabine.11 Loading decitabine in a nanogel formulation has 
also been tested. The antiproliferative activity of decitabine, 
evaluated on leukemia cells, was enhanced by .2-fold. This 
could be due to the increased proportion of cells arrested in 
the G2/M phase for nanogel formulations relative to that 
observed for decitabine in solution.12
Lipid-core nanocapsules (LNCs), with a structure close to 
that of lipoproteins, were developed by our laboratory .15 
years ago. Their production is based on a phase-inversion 
temperature process.13 These nanoparticles have demon-
strated great potential for the encapsulation of lipophilic 
drugs14 and biopolymers.15 Such nanomedicines show a good 
toxicity profile16,17 and can be produced in large batches.18 
We were, thus, interested in encapsulating decitabine in these 
nanocarriers.19 However, the encapsulation of decitabine 
alone has only resulted in low-encapsulation yields.
Our aim was to develop a decitabine prodrug designed 
to be entrapped in a lipid-based nanoparticle formulation 
to enhance the stability of decitabine in blood and prolong 
contact time with the target cells.
Materials and methods
chemicals
Decitabine was purchased from LC laboratories (Woburn, 
MA, USA). Labrafac® WL1349 (caprylic-capric acid triglyc-
erides) and Transcutol® HP (highly purified diethylene glycol 
monoethyl ether) were kindly provided by Gattefossé (Saint-
Priest, France). Kolliphor® HS15 (a mixture of free poly-
ethylene glycol [PEG] 660 and PEG 660 hydroxystearate) 
was kindly supplied by BASF (Angerville, France). Sodium 
chloride was purchased from Prolabo (Fontenay-Sous-Bois, 
France). Formic acid, Tween® 20 (sorbitan monolaurate), 
potassium chloride, sodium hydroxide, disodium hydro-
gen phosphate, dimethylsulfoxide (DMSO), potassium 
dihydrogen phosphate, dicyclohexylcarbodiimide (DCC), 
 hydrochloric acid, dimethylformamide (DMF), deuterated 
DMSO, lauric acid, 4-(dimethylamino) pyridine (DMAP), 
potassium chloride, and propidium iodide were purchased 
from Sigma-Aldrich (St Quentin-Fallavier, France). RNAse 
A was obtained from Fisher Scientific (Illkirch, France). 
Deionized water was obtained from a Milli-Q plus system 
(Merck-Millipore, Darmstadt, Germany). Absolute ethanol, 
acetonitrile LC/MS grade, and methanol LC/MS grade were 
purchased from Biosolve (Dieuze, France). Methanol and 
dichloromethane (DCM) laboratory reagent grades were 
obtained from Fisher Chemical (Illkirch, France).
Decitabine (c12)2 synthesis
Decitabine (C12)
2
 was obtained after magnetic stirring at room 
temperature of lauric acid (7.02 g), DCC (5.42 g), and DMAP 
(107 mg) in 50 mL DMF. After total dissolution, decitabine 
(1 g) was added to the mixture and magnetic stirring was 
continued for 24 hours at room temperature. The reaction was 
monitored by thin-layer chromatography (DCM-methanol 
90:10 v/v). A white precipitate was obtained (Figure 1).
After filtration on cotton wool, the precipitate was washed 
twice with 10 mL DMF. DMF present in the filtrate was 
evaporated under vacuum (Rotavapor® R-300, Buchi, Suisse) 
at 30°C, and the residues purified on a silica gel column with 
a first elution in DCM (2 L), followed by a second elution 
in DCM-methanol 99:1 v/v (3 L). The elution of decitabine 
(C12)
2
 was followed by thin-layer chromatography 
(DCM-methanol 90:10 v/v).
Pure fractions were then collected, and the solvents 
evaporated under vacuum to obtain a white product. 
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The molecular weight of the obtained product was deter-
mined using a microToFQII apparatus (Bruker Daltonics 
GmbH, Bremen, Germany) by electrospray positive ioniza-
tion. 1H-NMR spectra were recorded on an Avance DRX 
500 MHz (Bruker Daltonics GmbH, Bremen, Germany) in 
deuterated DMSO.
lNc formulation
LNCs were obtained according to a phase-inversion pro-
cess previously developed by Heurtault et al13 with minor 
modifications. Briefly, blank LNCs were obtained after 
mixing Labrafac® WL1349 (14.3% w/w), sodium chloride 
(1.5% w/w), Kolliphor® HS15 (32.7%), and water (34.7%). 
Three heating and cooling cycles between 65°C and 85°C 
were performed with magnetic stirring. During the last cool-
ing cycle, at 85°C, a mixture composed of Span® 20 and 
Transcutol® HP (50:50 w/w) was added (16.8% w/w). Finally, 
tempering was induced at 55°C with 5 mL 4°C water. Magnetic 
stirring was then maintained for 5 minutes at room temperature 
and the formulations stored at 4°C for further evaluation.
The same procedure was used for decitabine (C12)
2
-
loaded LNCs, except prior solubilization of decitabine (C12)
2
 
was performed at 50°C for 1 hour under magnetic stirring 
in the mixture composed of Span® 20 and Transcutol® HP 
at 40 mg/g (Figure 2).
chromatographic methods
Determination of decitabine (c12)2 concentrations
A liquid chromatography method using tandem mass 
spectrometry (LC-MS/MS) was developed to quantify 
decitabine (C12)
2
. It was performed on an Alliance® 2695 
system (Waters, Saint-Quentin-en-Yvelines, France) with 
an Uptisphere C18-ODB 150×2.0 mm, 5 µm column (Inter-
chrom, Montluçon, France). The mobile phase consisted of 
a phase A (0.1% formic acid in acetonitrile) and a phase B 
(0.1% formic acid in methanol) in an isocratic mode (A:B 
70:30 v/v). The flow rate was set to 0.4 mL/min for a run 
time of 6 minutes. The injection volume was 10 µL. The 
total HPLC effluent was directed into a Quattro Micro® 
triple quadrupole mass spectrometer (Waters). Ionization 
Figure 1 Decitabine (c12)2 synthesis.
Abbreviations: Dcc, dicyclohexylcarbodiimide; DMaP, 4-(dimethylamino) pyridine.
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Figure 2 Preparation of lipid nanocapsules loaded with decitabine (c12)2 by phase inversion temperature.
Abbreviation: lNcs, lipid-core nanocapsules.
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was achieved with an electrospray in the positive ion mode. 
The mass spectrometer was operated in the multiple reaction 
monitoring mode. The (M–H)+m/z transition for decitabine 
(C12)
2
 was 593.3.113.1. The entire system was controlled 
by Masslynx® software (Waters).
Calibration curves were obtained after solubilizing 
decitabine (C12)
2
 in methanol to obtain a stock solution of 
0.5 mg/mL. A sufficient quantity of the stock solution was 
then diluted in methanol to obtain a calibration curve between 
2.5 and 500 ng/mL (seven plots were used). A calibration 
curve was performed on each day of the analysis.
Determination of decitabine concentrations
The apparatus and software were the same as those used for 
decitabine (C12)
2
 quantification. An LC-MS/MS method 
previously published was used.19 The mobile phase consisted 
of a mixture of A) 0.1% formic acid in 10 mM ammonium 
acetate and B) 0.1% formic acid in acetonitrile, in gradient 
mode (Table 1). A 3-µm Nucleodur® HILIC column (Mach-
erey Nagel, Hoerdt, France), containing an ammonium-
sulfonic-acid-modified silica, was used with the temperature 
fixed at 25°C. The injection volume was set at 6 µL. The 
mass spectrometer was operated in the multiple reaction 
monitoring mode. The (M–H)+m/z transition for decitabine 
was 229.0.113.0.
Physiochemical characterization of the 
lNc formulations
size and polydispersity index measurements
The size and polydispersity index (PDI) of blank LNCs 
and decitabine (C12)
2
-loaded LNCs were determined by 
dynamic light scattering on a Zetasizer® Nano series DTS 
1060 (Malvern Instruments S.A., Worcestershire, UK) after 
dilution in deionized water (1:60 v/v). PDI measurements 
were used to evaluate the size distribution. Three consecutive 
measurements were systematically performed.
Drug encapsulation efficiency and drug loading
LNCs were filtered through 0.22 µm polyethersulfone 
syringe filters (Clearline®, Issy-les-Moulineaux, France). 
Decitabine (C12)
2
-filtrate concentrations, corresponding to 
the loaded drug, were determined after dilution in methanol 
to destabilize the LNCs and release the decitabine (C12)
2
. 
Decitabine (C12)
2
 concentrations were then determined by 
LC-MS/MS according to the method described above. The 
efficiency of drug loading, corresponding to the proportion 
of the drug encapsulated over the total drug concentration, 
was then determined.
stability studies
In phosphate-buffered saline solution
A volume of decitabine (C12)
2
-loaded LNCs (1 mL) was 
diluted in 59 mL PBS adjusted to pH 7.4, containing diso-
dium hydrogen phosphate (10 mM), potassium dihydrogen 
phosphate (1.8 mM), sodium chloride (137 mM), potassium 
chloride (2.7 mM), and hydrochloric acid to adjust the pH 
(experiments were performed in triplicate). Beakers were 
placed at 37°C under agitation. At pre-defined time points 
(T0, 2, 4, 8, 12, 24, and 48 hours), the efficiency of decitabine 
(C12)
2
 encapsulation and drug loading were determined by 
LC-MS/MS after filtration. The size and PDI of the LNCs 
were also evaluated over time.
Residual decitabine (C12)
2
 concentrations in PBS were 
determined. The decitabine (C12)
2
 concentration in PBS at 
the initial timepoint (T0) was considered to be 100%.
In human plasma
The stability of decitabine (C12)
2
-loaded LNCs in human 
plasma taken from healthy volunteers (provided by the 
Etablissement Français du Sang, Nantes, France) was 
evaluated. Formulations were first diluted 10-fold in water. 
A volume of 125 µL of the formulation was then mixed with 
2 mL plasma (experiments were performed in triplicate). 
Samples were then placed in a beaker and the temperature 
was maintained at 37°C. The experiment was conducted for 
24 hours. At each time point (0, 2, 4, 6, 9, and 24 hours), 
40 µL plasma was removed, diluted 10 times in acetoni-
trile, and centrifuged 10 minutes at 9,500×g (5810 R, Eppen-
dorf, Montesson, France). Supernatants were then collected 
and diluted 10-fold in methanol, and the decitabine (C12)
2
 
concentrations determined.
Residual decitabine (C12)
2
 concentrations were deter-
mined in human plasma. The decitabine (C12)
2
 concentration 
at the initial timepoint (T0) was considered to be 100%.
Decitabine concentrations were also evaluated to detect 
the appearance of decitabine over time from decitabine 
Table 1 gradient elution in the lc-Ms/Ms method 
Time 
(minutes)
Phase A (%) Phase B (%) Flow 
(mL/minutes)
0.00 20 80 0.200
6.00 28 72 0.200
6.10 28 72 0.300
7.00 20 80 0.300
12.00 20 80 0.300
Note: Mobile phase a consisted of a mixture of 10 mM ammonium acetate and 
0.1% formic acid (v/v) and mobile phase B consisted of acetonitrile and 0.1% 
formic acid (v/v).
Abbreviation: lc-Ms/Ms, liquid chromatography method using tandem mass 
spectrometry.
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(C12)
2
 transformation. The same protocol was applied, except 
the last dilution was performed in methanol and by a factor 
of two instead of 10.
cell experiments
cell culture
The human erythroleukemia cell line (HEL) (LGC Standard, 
Molsheim, France) was maintained in Roswell Park Memo-
rial Institute medium 1640 (RPMI), supplemented with 10% 
FBS (Gibco, Fisher Scientific France, Illkirch, France) and 
1% antibiotics, in a humidified incubator with an atmosphere 
containing 5% CO
2
 at 37°C.
In vitro cell proliferation
The antiproliferative capacity of decitabine (C12)
2
-loaded 
LNCs was compared to that of blank LNCs or decitabine or 
decitabine (C12)
2
 in solution.
Cells were plated at 5×103 cells/well in 96-well plates. 
After 24 hours, cells were treated with free-decitabine (C12)
2
, 
decitabine (C12)
2
-loaded LNCs, blank LNCs, or a solution 
of decitabine. Various concentrations of decitabine (C12)
2
 
from 12.5 to 2,500 nM were tested. For the decitabine solu-
tion, the concentration ranged from 5 to 1,000 nM. For blank 
LNCs, the same range of excipient concentrations as those 
for decitabine (C12)
2
-loaded LNCs was tested. Cells cultured 
with medium alone were used as the 100% viability control. 
Three independent experiments were conducted, each with 
quadruplicate samples.
After 72 hours, the plates were centrifuged, culture 
medium removed, and cell pellets frozen at -80°C for at 
least 48 hours. Cell proliferation was then evaluated with 
the Cyquant® cell-proliferation assay kit, according to the 
manufacturer’s instructions (Fisher Scientific).
cell-cycle analysis
Cells (HEL) were cultured in 12-well plates at 5×104 cells/
well. After 24 hours, cells were treated with decitabine 
in solution (1,000 nM), decitabine (C12)
2
-loaded LNCs 
(2,500 nM), or blank LNCs with an equivalent excipient 
concentration as that of the decitabine (C12)
2
-loaded LNCs.
After 72 hours, cells were collected and centrifuged at 
200×g for 5 minutes. Pellets were then washed in PBS and 
fixed in 70% cold ethanol. Fixed cells were washed in PBS 
and incubated for 15 minutes at room temperature in the dark 
in a PBS staining solution containing 40 µg/mL propidium 
iodide and 100 µg/mL RNAse A.
Samples were then analyzed on a BD FACSCANTO II 
system (BD Biosciences, Le Pont de Claix, France), and prop-
idium iodide incorporation estimated using BD FACSDiva 
software (BD Biosciences, Le Pont de Claix, France). Cell-
cycle analysis data were processed using Flowlogic V7.2 
software (Inivai Technologies, Victoria, Australia) and the 
Dean Jett Fox model.
In vivo study
animals
The study was approved by the ethical committee of Pays 
de la Loire, France, under the number APAFiS 10751. 
Experiments were carried out in strict accordance with the 
regulations of the French Ministry of Agriculture and were in 
accordance with the Principles of Laboratory Animal Care. 
Experiments were performed on male Wistar rats weighing 
between 222 and 410 g, aged 8–11 weeks, obtained from 
the Service Commun d’Animalerie Hospitalo-Universitaire 
(Angers, France). The rats had access to water and food ad 
libitum prior to the experimental procedure and were fasted 
3 hours before experiments.
Pharmacokinetics analysis
Each group was composed of five animals. Animals were 
slowly injected via the penis vein under inhalational anes-
thesia (isoflurane-oxygen). Decitabine (C12)
2
-loaded LNCs 
(12.5 mg/kg) or decitabine (5 mg/kg) in a saline solution 
were injected. Doses were adapted with respect to the 
2.5 molar ratio between decitabine (C12)
2
 and decitabine 
and corresponded to 21 µmol/kg. Blood samples were then 
collected via the tail vein at 2, 30, and 60 minutes and 2, 5, 
and 6 hours after injection, into heparinized tubes. Samples 
were centrifuged at 150×g for 5 minutes at room tempera-
ture and the supernatants (plasma) diluted in acetonitrile 
(5-fold for decitabine samples and 10-fold for decitabine 
(C12)
2
 samples) and centrifuged at 15,000×g for 10 minutes. 
Supernatants were collected and diluted in methanol (2-fold 
for decitabine samples and 20-fold for decitabine (C12)
2
 
samples) and analyzed by LC-MS/MS.
Calibration curves were performed in rat plasma from 25 
to 850 ng/mL decitabine or 50 to 1,000 ng/mL decitabine 
(C12)
2
.
The main pharmacokinetic parameters of decitabine were 
determined using Kinetica® 5.1 software (Thermo Scientific, 
Philadelphia, PA, USA). Intravenous non-compartmental 
analysis was used to evaluate these parameters for decitabine 
and decitabine (C12)
2
, and extravascular non-compartmental 
analysis was used to evaluate those of decitabine after 
decitabine (C12)
2
-loaded LNC injection. The maximal 
concentration (C
max
), time to reach the maximum concentra-
tion (T
max
), area under the plasma concentration-time curve 
(AUC), and mean residence time (MRT) were determined.
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statistical analysis
Results are expressed as the mean±standard deviation 
(SD) or standard error of the mean (SEM) for in vivo 
experiments. Group comparisons were performed using the 
Mann–Whitney test, P,0.05 was considered to be statisti-
cally significant.
Results
Decitabine (c12)2 synthesis
We obtained a white dried product. The yield of the 
chemical synthesis was estimated to be 50%. After elemental 
analysis, we determined the molecular weight of the 
obtained purified product to be 592 g/mol, confirming the 
chemical structure of decitabine (C12)
2
 (calculated molecular 
weight=592.81 g/mol).
Elemental analysis showed the purity to be 98%: 1H 
NMR (300 MHz, deuterated DMSO): δ 0.75 (6 H, t), 1.15 
(40 H, m), 1.5 (4 H, m), 2.25 (4 H, m), 2.30 (2 H, dd), 4.10 
(1 H, m), 4.20 (2 H, m), 5.20 (1 H, m), 5.90 (1 H, t), 7.60 
(-NH2, 2 hours, m), 8.25 (1 H, s).
characterization of the lNcs
We determined the efficiency of encapsulation and drug load-
ing following the formulation of blank LNCs or decitabine 
(C12)
2
-loaded LNCs. The size, PDI, encapsulation efficiency, 
and drug loading are presented in Table 2. The drug loading 
is 5.8 mg/mL of formulation. The drug loading presented as 
the percentage of loaded drug amount relative to the drug 
and nanocarrier material is 1.63% w:w.
Encapsulation of decitabine (C12)
2
 into the LNCs did not 
modify the size of the nanoparticles relative to that of blank 
LNCs. The drug encapsulation efficiency was unchanged 
after 15 days (called “matured LNCs” in Table 2). However, 
drug loading decreased by a factor of 1.5, due to the degrada-
tion of decitabine (C12)
2
 over time.
stability studies
In PBs
We evaluated the encapsulation efficiency and drug load-
ing of decitabine (C12)
2
-loaded LNCs for 48 hours in PBS 
(Figure 3A). The encapsulation efficiency was unaltered 
after 48 hours at 37°C. However, decitabine (C12)
2
 slowly 
degraded over time. After 48 hours, half of the initial drug 
concentration was recovered. Thus, drug loading was reduced 
to half of that initially. The formulations were stable for the 
duration of the stability study, without modification of size 
or PDI (Figure 3B).
In human plasma
We evaluated the stability of decitabine (C12)
2
-loaded LNCs 
in human plasma (Figure 4). Decitabine (C12)
2
 slowly 
degraded over time, whereas the decitabine concentration 
increased, reaching a maximum after 6 hours. A plateau was 
then maintained for 3 hours before the decitabine started to 
degrade. This experiment confirmed the expected transfor-
mation of decitabine (C12)
2
 to decitabine. However, only 
10% of the maximal theoretical decitabine concentration 
was reached, indicating that not all decitabine (C12)
2
 was 
transformed into decitabine over time.
cell culture experiments
cell proliferation study
We compared the antiproliferative activity of decitabine 
(C12)
2
-loaded LNCs to that of decitabine (C12)
2
 in solution, 
decitabine in solution, and blank LNCs by measuring cell 
proliferation after 3 days of contact with various concentra-
tions of the compounds/LNCs (Figure 5). Blank LNCs were 
non-toxic at concentrations between 26 and 105 µg/mL, 
whereas there was a trend toward antiproliferative activity 
above 200 µg/mL. Exposure to above 50 nM decitabine or 
125 nM decitabine (C12)
2
, either free or loaded in LNCs, 
decreased cell viability. Cell viability was systematically and 
significantly lower when the decitabine (C12)
2
 was loaded 
than when it was in solution at concentrations above 250 nM. 
Finally, the antiproliferative activity of decitabine was greater 
than that of decitabine (C12)
2
, free or loaded into LNCs.
cell-cycle analysis
We then performed cell-cycle analysis on HEL cells 
(Figure 6). Untreated cells (RPMI alone) or those treated 
Table 2 Physiochemical characterizations of blank and loaded lNc formulations (n=3)
LNC formulations Size (nm) PDI Encapsulation efficiency (%) Drug loading (mg/mL)
Blank lNcs 27.54±0.19 0.05±0.01 – –
Decitabine (c12)2-loaded lNcs 27.45±0.05 0.05±0.01 100±0.7 5.8±0.5
Matured decitabine (c12)2-loaded lNcs
a 28.32±0.38 0.07±0.01 103±0.09 4.0±0.4
Note: aFormulations were stored at 4°c for 15 days.
Abbreviations: lNc, lipid-core nanocapsule; PDI, polydispersity index.
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with blank LNCs showed ,10% of the cells in the G2/M 
phase of the cell cycle. As expected, cells treated with 
decitabine showed a higher proportion of cells arrested in 
G2/M (17.2%). Treatment of the cells with decitabine (C12)
2
-
loaded LNCs (2,500 nM) gave similar results, with 14.6% 
of the cells arrested in G2/M, which was not significantly 
different from that of treatment with decitabine (1,000 nM) 
(P=0.25, Mann–Whitney test).
Pharmacokinetic analysis
We intravenously administered the same molar concentra-
tions of decitabine and decitabine (C12)
2
 to rats. Plasma 
Figure 3 Physiochemical behavior of decitabine (c12)2 PBs-loaded lNcs in PBs at 37°c for 48 hours (n=3). Drug loading and residual decitabine (c12)2 concentration 
remained unchanged for the first 12 hours and decreased thereafter (A), whereas the size and PDI remained unchanged for 48 hours (B).
Abbreviations: lNc, lipid-core nanocapsule; PDI, polydispersity index.
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Figure 4 Decitabine (c12)2 stability in human plasma. Decitabine (c12)2-loaded lNcs were incubated in human plasma at 37°c for 24 hours. The decitabine-(c12)2 
concentration at the initial timepoint (T0) was considered to be 100% (n=3).
Abbreviation: lNcs, lipid-core nanocapsules.
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Figure 5 cell proliferation study of hel following exposure to various concentrations of blank lNcs (indicated below each bar graph), decitabine solution, decitabine 
(c12)2-loaded lNcs, or decitabine (c12)2 solution. cells cultured with medium alone were considered to correspond to 100% viability (n=3 plates, quadruplicate).
Note: *P,0.05 Mann–Whitney test.
Abbreviations: hel, human erythroleukemia cell line; lNcs, lipid-core nanocapsules.
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Figure 6 cell-cycle analysis of hel cells following exposure to rPMI (A), blank lNcs (B), decitabine solution (C), or decitabine (c12)2-loaded lNcs (D) also as expressed 
as a percentage of cells blocked in g2/M phase (E) (n=3 plates, in triplicate).
Note: *P,0.05 Mann–Whitney test vs cells treated with rPMI.
Abbreviations: hel, human erythroleukemia cell line; lNcs, lipid-core nanocapsules; rPMI, roswell Park Memorial Institute medium 1640.
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concentrations of decitabine (C12)
2
 were significantly higher 
(8-fold) than those of decitabine after 2 minutes (Figure 7). 
The plasma concentration of both then decreased rapidly, 
corresponding to a very short MRT (Table 3). The MRT 
of decitabine (C12)
2
 was significantly shorter than that of 
decitabine (P=0.008). However, the MRT of decitabine was 
significantly prolonged when the decitabine (C12)
2
-LNC for-
mulation was injected (P=0.008). An increase in decitabine 
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concentrations over time (Figure 7) confirmed the metabolism 
of decitabine (C12)
2
 to decitabine; the maximal concentra-
tion of decitabine was reached 84±33 minutes after injection. 
The C
max
 of decitabine was lower when it was administered 
as a solution than in its encapsulated form (Table 3). The 
terminal half-lives (T
1/2
) were calculated from the three last 
points of the curves and were as follows: T
1/2
 of decitabine: 
146±22 minutes; T
1/2
 of decitabine (C12)
2
: 64±48 minutes, 
and T
1/2
 of decitabine after decitabine (C12)
2
 transformation: 
171±14 minutes. This last value does not significantly differ 
from the half-life of free decitabine (P.0.05).
Discussion
In clinical trials, decitabine modestly increased the overall 
survival of older AML patients over that of supportive care.20 
The blood residence time of the drug after intravenous admin-
istration is from 15 to 25 minutes due to its chemical insta-
bility and rapid degradation by cytidine deaminase.7 Here, we 
synthesized a prodrug to overcome such degradation. Lauric 
acid was selected to form an ester bond with decitabine. 
Modified decitabine was obtained by adding two alkyl chains 
to the 3′ and 5′ hydroxyl groups of the decitabine molecule. 
Finally, we obtained a decitabine (C12)
2
 molecule, with a 
molecular weight of 592 g/mol. The yield of the chemical 
synthesis was limited to 50%, probably due to the well-known 
chemical instability of decitabine under various conditions 
(acid, alkaline, and heat).6,21–23 This chemical modification 
confers a more lipophilic structure to the molecule than that of 
decitabine, allowing its encapsulation into LNCs, which are 
organic solvent-free nanoparticles.24 Gemcitabine, another 
deoxycytidine analog, has been largely chemically modified 
with numerous different chemical modifications.25 Among 
them, esterification of fatty acids on the 5′ position prolonged 
the cell retention time, rendered cellular internalization inde-
pendent of the human equilibrative nucleoside transporters 
(hENT), and improved efficacy in gemcitabine-resistant cell 
lines.26,27 The activity of decitabine inversely correlates with 
hENT expression, demonstrating its cellular internalization 
by those transporters.28 Thus, if the cell penetration pathway 
of the 5′ fatty acid ester of decitabine designed in this study 
is hENT independent, as shown for the 5′ fatty acid ester 
of gemcitabine, then resistance to chemotherapy could be 
overcome.
Figure 7 evolutions of plasma concentrations of active pharmaceutical ingredients over time following IV bolus administration of a decitabine solution or a decitabine (c12)2-
loaded lNcs solution.
Note: results are presented as mean±seM (n=5 for each group).
Abbreviations: aPI, active pharmaceutical ingredient; Dac, decitabine; IV, intravenous; lNcs, lipid-core nanocapsules; seM, standard error of the mean.
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Table 3 Main pharmacokinetic parameters of decitabine 
and decitabine (c12)2 following IV administration of 5 mg/kg 
decitabine or 12.5 mg/kg decitabine (c12)2
Parameters Decitabine Decitabine 
(C12)2
Decitabine (after 
decitabine (C12)2-
loaded LNC injection)
cmax (µM) 36±8 307±80 6±1
aUc (µM×h) 82±15 246±74 31±3
MrT (h) 3.4±0.4 1.5±0.9 4.5±0.3
Tmax (min) 2±0 2±0 84±33
Note: Data were obtained using an intravascular non-compartmental analysis 
following IV administration of decitabine (c12)2-loaded lNcs, except for decitabine 
parameters for which an extravascular non-compartmental analysis was performed.
Abbreviations: aUc, area under the plasma concentration-time curve; IV, 
intravenous; lNcs, lipid-core nanocapsules; MrT, mean residence time.
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The most advanced chemically modified form of 
decitabine in clinical trials is guadecitabine. Decitabine is 
released after gradual cleavage of the phosphodiester bond 
present in the structure and the in vivo exposure time was 
prolonged.29 Similarly, decitabine (C12)
2
, developed here, 
with two ester linkages, may gradually release decitabine in 
the blood once it is introduced into the blood stream. How-
ever, the modified decitabine was not soluble in water, and 
drug formulation was necessary for its administration. One 
possibility was surfactant adjunction or encapsulation into 
nanoparticles. Nanoparticles have several advantages, such as 
protecting the drug from several degradation pathways. Our 
group has previously developed LNCs that can encapsulate 
lipophilic drugs.14,30,31 The calculated log P of decitabine 
(C12)
2
 is 9.7, which explains its capacity to be well encapsu-
lated in lipid-core nanocapsules. Indeed, drug loading of the 
prodrug improved over that of a previous formulation with no 
chemical modification of decitabine (log P=-2.2), for which 
drug loading of only ~0.5 mg/mL was obtained vs 2.3 mg/mL 
in the present study.19 In AML, decitabine is administered at a 
dose of 20 mg/m2 body surface area. With such a formulation, 
a volume of ,9 mL/m2 body surface area is required to obtain 
a potential clinical effect. Lipid-based nanocarriers were also 
developed by Neupane et al32 using a high-pressure homog-
enizer technique. The encapsulation efficiency was over 80%, 
but lower than that of our prodrug strategy. Vijayaraghavalu 
and Labhasetwar12 developed another nanocarrier formula-
tion, corresponding to a nanogel. Drug loading of ~6% w/w 
was obtained, but without considering the water content in 
the formulation. Our shelf-stability studies of decitabine 
(C12)
2
-loaded LNCs in suspension demonstrated a decrease 
of the relative decitabine (C12)
2
 concentration after 15 days, 
with stable encapsulation efficiency. A freeze-drying process 
may be used to allow the storage of formulations for several 
months, as previously described for LNCs.33
We then studied the stability of the formulation in several 
media. We first determined the stability in PBS maintained at 
37°C. The decitabine (C12)
2
 concentration was stable; .75% 
of the initial concentration was recovered after 24 hours. 
Decitabine degradation in phosphate buffer was previously 
studied by Lin et al,21 who reported recovery of ,50% of the 
initial concentration after 24 hours at 37°C. The chemical 
modification of decitabine associated with its encapsulation 
into LNCs led to its reduced degradation. This is in accor-
dance with previous studies demonstrating that decitabine 
prodrugs enhance the stability of the drug in buffers, even 
if instability is generally observed after several hours.34–36
Several studies using cytidine deaminase inhibitors to 
increase the time of exposure to decitabine have also been 
published.37,38 We chose an alternative strategy using nano-
carriers, as previously performed to protect cytarabine using 
a liposomal formulation.9 We performed a stability study 
of the decitabine (C12)
2
-loaded LNCs in human plasma 
to demonstrate the protective activity of the nanocarrier. 
The decitabine (C12)
2
 concentration decreased, but the 
decrease was slower than that found in a previous study 
using a decitabine solution under the same conditions, for 
which ,40% of the initial concentrations were recovered 
after 6 hours.19 In addition, decitabine (C12)
2
 was cleaved 
to decitabine in human plasma, increasing the MRT. 
Stresemann and Lyko6 demonstrated that extended exposure 
to a hypomethylating agent enhanced DNA demethylation. 
The increased MRT of decitabine in plasma may, thus, 
enhance decitabine activity in vivo.
We then performed in vitro experiments on an acute 
myeloid leukemia cell line (HEL). We first performed cell 
proliferation assays and demonstrated that free decitabine 
(C12)
2
 decreased cell proliferation significantly less than 
a solution of decitabine. The antiproliferative activity 
of decitabine (C12)
2
 may require its transformation to 
decitabine. This effect was previously observed with a 
gemcitabine derivative.39 Blank LNCs were non-toxic at the 
highest concentrations tested, whereas cell proliferation was 
significantly decreased by treatment with a free decitabine 
solution or decitabine (C12)
2
-loaded LNCs. Moreover, the 
antiproliferative activity of decitabine (C12)
2
-loaded LNCs 
was significantly higher than that of decitabine (C12)
2
 alone, 
confirming the potential of LNCs to increase drug activity.
This increased activity of the decitabine (C12)
2
-loaded 
LNCs relative to that of free decitabine (C12)
2
 could be due 
to increased cellular penetration of the drug via the active 
uptake of LNCs mediated by clathrin/caveolae-independent 
pathways.40,41
Decitabine arrests leukemic cells in the G2/M phase.42–44 
Although decitabine was modified, cell-cycle analysis dem-
onstrated a trend toward a higher proportion of cells in G2/M 
after treatment with decitabine or decitabine (C12)
2
-loaded 
LNCs. The capacity of decitabine to arrest cells in the G2/M 
phase was, thus, not altered by chemical modification.
We finally compared the pharmacokinetic parameters of 
decitabine (C12)
2
-loaded LNCs to those of decitabine. The 
observed pharmacokinetic parameters of decitabine are in 
accordance with those previously published.45,46 The C
max
 
of the two drugs were significantly different 2 minutes after 
intravenous administration, with 8-fold more decitabine 
(C12)
2
 available than decitabine. However, decitabine 
(C12)
2
-loaded LNCs were then rapidly eliminated, and the 
MRT of decitabine (C12)
2
 was significantly lower than that 
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of decitabine. This rapid elimination of the drug is probably 
due to the rapid accumulation of particles in the liver.47 
Nevertheless, the MRT of decitabine was significantly pro-
longed after decitabine (C12)
2
-loaded LNC administration. 
However, the AUC of decitabine remained lower with LNC 
administration than when administered as a free solution. 
PEGylation of the particles could increase the MRT and AUC 
of decitabine by delaying the transformation of decitabine 
(C12)
2
 to decitabine. Currently, the PEGylation of LNCs 
induced by Kolliphor® HS15 is insufficient and the MRT of 
decitabine (C12)
2
-loaded LNCs has to be enhanced by the 
PEGylation of LNCs with a larger PEG chain.48 Indeed, Groo 
et al49 have already demonstrated that such PEGylation of 
LNCs enhances the MRT by a factor of 1.5.
Conclusion
We chemically modified decitabine and combined this with 
its encapsulation into LNCs. This strategy increased the 
shelf stability of decitabine and reduced its sensitivity to 
cytidine deaminase in vitro. In vivo pharmacokinetics evalu-
ations confirmed the potential of such a strategy to enhance 
the MRT of decitabine. Further modifications of the LNCs 
may improve their pharmacokinetic parameters, especially 
the maximum blood concentrations and AUC. This would 
be useful for future pharmacological and biodistribution 
evaluations.
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